Indivior PLC【INDV】株式ニュース | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

Indivior PLC (INDV)

11.85

-0.24

(-1.99%)

終値： 1月11日 6:00AM

11.85

-0.005

( -0.04% )

取引時間後: 7:30AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior PR...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection...

1
2
次へ

Monksdream

Monksdream 9月前

Renee

IZQVF: effective Oct. 10,2022 a one for 5 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

cash4

March 23, 2020
Statement on the Coronavirus and Global Supply of Medicines
Indivior is closely monitoring developments relating to COVID-19 (novel coronavirus) outbreak.
Our priority remains the ongoing supply of medicines to healthcare providers and patients, the
health and safety of our employees and the well-being of the patients we serve.
We are actively managing our global supply chains to minimize any potential disruption. Our
executive management and supply team are together working with internal and external business
partners and regulatory authorities to assess and mitigate the potential impact of COVID-19. We are
committed to helping ensure that patients will continue to have an ongoing supply of their
medication. Based on our assessment and environment we do not currently expect to have any
material supply interruptions.
We are also following guidelines provided by international health authorities and all global, national
and local government mandates regarding measures to keep our workforce and communities safe.
We have instituted a remote work policy for office and field-based staff leveraging all available
technology to ensure essential activities will continue to provide patients, healthcare providers and
other key stakeholders with the supports they need.
We will continue to monitor the situation closely, placing the needs of patients first at all times.

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約